BioSpace News Archive

Cybin Corp. (the “Company or “Cybin”), a life sciences company advancing psychedelic pharmaceuticals, is pleased to announce that Mr. Doug Drysdale has been appointed as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005388/en/ Mr. Doug Drysdale, CEO of Cybin Corp. (Photo: Business Wire) Doug has more than 30 years of experienc

Various Atara Posters Being Presented at ACTRIMS-ECTRIMS Further Elucidate the Role of EBV in MS Company to Host Live Conference Call and Webcast to Review MS Data Presentation on Friday, September 11, 2020 at 8:30 a.m. ET/5:30 p.m. CEST SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for pa

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) is pleased to announce that it has received confirmation from the Canadian Stock Exchange (the “Exchange”) that its common shares will resume trading on Tuesday, September 1, 2020. Trading on the OTC is expected to resume shortly thereafter. The Exchange’s Listing Committee has approved Betterlife’s new Listing Statement after having received satisfactor

Bicycle Therapeutics Announces First Patient Dosed in Oxurion’s Phase II Trial Using a Novel Bicycle ® -based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema CAMBRIDGE, England & BOSTON--( BUSINESS WIRE )-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that the first

Intabio, Inc., a developer of analytical solutions that provides profound efficiency gains across all stages of biopharmaceutical development and manufacturing, today released details of several upcoming scientific presentations that highlight the power of Intabio’s Blaze system. The presentations all are associated with the 17

Olive Diagnostics, a digital healthcare and diagnostic solutions provider, transforms in-home urinalysis with the world’s only functional, hands-free, non-invasive prototype: K2. K2 mounts to any toilet, detecting urine’s molecular composition, generating secure, personalized diagnostic data, directly linked via mobile app.

reVision Therapeutics, Inc. (“reVision” or the “Company”), today announced that it has signed an exclusive license agreement with Cornell University (“Cornell”) for the development and commercialization of Cornell’s proprietary technology for the treatment of Stargardt disease, a genetic disorder that affects central vision.

Walgreens brand diclofenac gel, prescription-strength arthritis pain relief in topical form, now available nationwide

Atorus Research, a clinical analytics company that builds tools and solutions that efficiently facilitate data management and biometric activities, is pleased to announce the release of their second R package, Tplyr.

Pear Therapeutics, Inc. today announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the Citi 15th Annual BioPharma Virtual Conference on Tuesday, September 8 at 10:40 a.m. Eastern Time.